Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma, or MPM.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Wolfe starts Merck at Peer Perform, notes competitive overhangs
- Merck initiated with a Peer Perform at Wolfe Research
- PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
- Merck enters exclusive global license for LM-299
- Zentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson
Questions or Comments about the article? Write to editor@tipranks.com